Myo-inositol products in polycystic ovary syndrome (PCOS) treatment

Quality, labeling accuracy, and cost comparison

Enrico Papaleo, M. Molgora, L. Quaranta, M. Pellegrino, F. De Michele

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objectives: To evaluate the labeling accuracy of four myo-inositol products, designed for polycystic ovary syndrome (PCOS) treatment, available on the Italian market and to perform a cost comparison based on myo-inositol content in milligrams for products analyzed. Materials and Methods: Four (4) myo-inositol products (3 sachet and 1 tablet formulations) were dissolved using water, and each sample was analyzed for myo-inositol content using a high-performance liquid chromatography (HPLC) method with index refraction detector. The amount of myo-inositol per purchased product was then divided into its purchase price in order to make cost comparisons between the products based on a 2 and 4 g/day dose. Results: A significant difference in the myo-inositol content, compared with the labeling was found for the products. Only 1 product contained more than 95% of the myo-inositol content claimed on the label, and there was a product with less than 75% of the labeling amount. Based on a 2-g myo-inositol per day dose, the cost of a 30-day supply ranged from € 20,77 and € 71,86, after correction by actual amount of myo-inositol. Conclusion: There is a lack of conformity between declared and actual amount of myo-inositol among the products tested and the majority of the products contained less than 95% of labeled amounts. There should be a better control in the manufacturing process in order to ensure more quality and accuracy. Nowadays consumers cannot trust myo-inositol product labels to represent the product's content accurately or that product pricing is a reflection of myo-inositol content.

Original languageEnglish
Pages (from-to)165-174
Number of pages10
JournalEuropean Review for Medical and Pharmacological Sciences
Volume15
Issue number2
Publication statusPublished - Feb 2011

Fingerprint

Polycystic Ovary Syndrome
Inositol
Costs and Cost Analysis
Tablets
High Pressure Liquid Chromatography

Keywords

  • Clinical efficacy
  • Insulin resistance
  • Labeling accuracy
  • Myoinositol products
  • Polycystic ovary syndrome

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology (medical)

Cite this

Myo-inositol products in polycystic ovary syndrome (PCOS) treatment : Quality, labeling accuracy, and cost comparison. / Papaleo, Enrico; Molgora, M.; Quaranta, L.; Pellegrino, M.; De Michele, F.

In: European Review for Medical and Pharmacological Sciences, Vol. 15, No. 2, 02.2011, p. 165-174.

Research output: Contribution to journalArticle

@article{27b289d81f8d4478865ebda0ca35d367,
title = "Myo-inositol products in polycystic ovary syndrome (PCOS) treatment: Quality, labeling accuracy, and cost comparison",
abstract = "Objectives: To evaluate the labeling accuracy of four myo-inositol products, designed for polycystic ovary syndrome (PCOS) treatment, available on the Italian market and to perform a cost comparison based on myo-inositol content in milligrams for products analyzed. Materials and Methods: Four (4) myo-inositol products (3 sachet and 1 tablet formulations) were dissolved using water, and each sample was analyzed for myo-inositol content using a high-performance liquid chromatography (HPLC) method with index refraction detector. The amount of myo-inositol per purchased product was then divided into its purchase price in order to make cost comparisons between the products based on a 2 and 4 g/day dose. Results: A significant difference in the myo-inositol content, compared with the labeling was found for the products. Only 1 product contained more than 95{\%} of the myo-inositol content claimed on the label, and there was a product with less than 75{\%} of the labeling amount. Based on a 2-g myo-inositol per day dose, the cost of a 30-day supply ranged from € 20,77 and € 71,86, after correction by actual amount of myo-inositol. Conclusion: There is a lack of conformity between declared and actual amount of myo-inositol among the products tested and the majority of the products contained less than 95{\%} of labeled amounts. There should be a better control in the manufacturing process in order to ensure more quality and accuracy. Nowadays consumers cannot trust myo-inositol product labels to represent the product's content accurately or that product pricing is a reflection of myo-inositol content.",
keywords = "Clinical efficacy, Insulin resistance, Labeling accuracy, Myoinositol products, Polycystic ovary syndrome",
author = "Enrico Papaleo and M. Molgora and L. Quaranta and M. Pellegrino and {De Michele}, F.",
year = "2011",
month = "2",
language = "English",
volume = "15",
pages = "165--174",
journal = "European Review for Medical and Pharmacological Sciences",
issn = "1128-3602",
publisher = "Verduci Editore",
number = "2",

}

TY - JOUR

T1 - Myo-inositol products in polycystic ovary syndrome (PCOS) treatment

T2 - Quality, labeling accuracy, and cost comparison

AU - Papaleo, Enrico

AU - Molgora, M.

AU - Quaranta, L.

AU - Pellegrino, M.

AU - De Michele, F.

PY - 2011/2

Y1 - 2011/2

N2 - Objectives: To evaluate the labeling accuracy of four myo-inositol products, designed for polycystic ovary syndrome (PCOS) treatment, available on the Italian market and to perform a cost comparison based on myo-inositol content in milligrams for products analyzed. Materials and Methods: Four (4) myo-inositol products (3 sachet and 1 tablet formulations) were dissolved using water, and each sample was analyzed for myo-inositol content using a high-performance liquid chromatography (HPLC) method with index refraction detector. The amount of myo-inositol per purchased product was then divided into its purchase price in order to make cost comparisons between the products based on a 2 and 4 g/day dose. Results: A significant difference in the myo-inositol content, compared with the labeling was found for the products. Only 1 product contained more than 95% of the myo-inositol content claimed on the label, and there was a product with less than 75% of the labeling amount. Based on a 2-g myo-inositol per day dose, the cost of a 30-day supply ranged from € 20,77 and € 71,86, after correction by actual amount of myo-inositol. Conclusion: There is a lack of conformity between declared and actual amount of myo-inositol among the products tested and the majority of the products contained less than 95% of labeled amounts. There should be a better control in the manufacturing process in order to ensure more quality and accuracy. Nowadays consumers cannot trust myo-inositol product labels to represent the product's content accurately or that product pricing is a reflection of myo-inositol content.

AB - Objectives: To evaluate the labeling accuracy of four myo-inositol products, designed for polycystic ovary syndrome (PCOS) treatment, available on the Italian market and to perform a cost comparison based on myo-inositol content in milligrams for products analyzed. Materials and Methods: Four (4) myo-inositol products (3 sachet and 1 tablet formulations) were dissolved using water, and each sample was analyzed for myo-inositol content using a high-performance liquid chromatography (HPLC) method with index refraction detector. The amount of myo-inositol per purchased product was then divided into its purchase price in order to make cost comparisons between the products based on a 2 and 4 g/day dose. Results: A significant difference in the myo-inositol content, compared with the labeling was found for the products. Only 1 product contained more than 95% of the myo-inositol content claimed on the label, and there was a product with less than 75% of the labeling amount. Based on a 2-g myo-inositol per day dose, the cost of a 30-day supply ranged from € 20,77 and € 71,86, after correction by actual amount of myo-inositol. Conclusion: There is a lack of conformity between declared and actual amount of myo-inositol among the products tested and the majority of the products contained less than 95% of labeled amounts. There should be a better control in the manufacturing process in order to ensure more quality and accuracy. Nowadays consumers cannot trust myo-inositol product labels to represent the product's content accurately or that product pricing is a reflection of myo-inositol content.

KW - Clinical efficacy

KW - Insulin resistance

KW - Labeling accuracy

KW - Myoinositol products

KW - Polycystic ovary syndrome

UR - http://www.scopus.com/inward/record.url?scp=79953245144&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953245144&partnerID=8YFLogxK

M3 - Article

VL - 15

SP - 165

EP - 174

JO - European Review for Medical and Pharmacological Sciences

JF - European Review for Medical and Pharmacological Sciences

SN - 1128-3602

IS - 2

ER -